Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Rhea-AI Summary

Acadia Pharmaceuticals (Nasdaq: ACAD) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. Eastern Time. The event will be held virtually, featuring a live audio-only webcast of Acadia's presentation and Q&A session, which can be accessed on their website and will be available for replay until February 11, 2022.

Acadia focuses on advancing neuroscience breakthroughs, including treatments for psychosis related to Parkinson's disease, dementia, schizophrenia, and Rett syndrome.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 10:30 a.m. Eastern Time, followed by a question and answer session.

The conference will be held virtually. A live audio-only webcast of Acadia’s presentation and question and answer session, along with accompanying slides, will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through February 11, 2022.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005096/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.

FAQ

When will Acadia Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Acadia Pharmaceuticals will present on January 11, 2022, at 10:30 a.m. Eastern Time.

How can I watch Acadia Pharmaceuticals' presentation at the conference?

You can access the live audio-only webcast of Acadia's presentation on their website under the investors section.

Until when will the Acadia Pharmaceuticals presentation be available for replay?

The archived recording will be available until February 11, 2022.

What is Acadia Pharmaceuticals known for?

Acadia Pharmaceuticals is known for developing the first approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis.

What are Acadia Pharmaceuticals' current development focuses?

Acadia is focused on treating psychosis in dementia, negative symptoms of schizophrenia, and Rett syndrome, among other CNS disorders.